Form 4: Director Leslie Norwalk Exercises NBIX Stock Units

Neurocrine Biosciences Director Leslie V. Norwalk acquired 1,659 shares of common stock through the vesting of restricted stock units.

Summary

• Director Leslie V. Norwalk acquired 1,659 shares of Neurocrine Biosciences (NBIX) common stock.
• The transaction occurred on May 21, 2026, via the exercise of restricted stock units (RSUs).
• The shares were acquired at a price of $0 per share as part of a previously granted equity award.
• Following this transaction, the director holds a total of 4,088 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents the standard fulfillment of director compensation agreements.

Positives

• Director maintains a direct equity stake in the company, aligning interests with shareholders.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

Not applicable as this is a routine disclosure of equity compensation.

Industry Context

StockSavvy.ai notes that routine equity vesting for directors is standard corporate governance practice in the biotechnology sector, reflecting typical compensation structures rather than strategic shifts.

Comparison to Industry Standards

• The transaction follows standard industry practices for director compensation via equity grants.
• The vesting schedule is consistent with typical annual equity awards for board members in mid-to-large cap biopharma companies.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine equity compensation event.

Next Steps

• None.

Key Dates

Keywords

NBIX, Neurocrine Biosciences, Insider Transaction, Form 4, Equity Compensation, Director Ownership